A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CEPI / collagen/epinephrine

[Related PubMed/MEDLINE]
Total Number of Papers: 45
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CEPI  (>> Co-occurring Abbreviation)
Long Form:   collagen/epinephrine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 [Clinical Significance of Platelet Closure Time in Patients with Multiple Myeloma]. BD, beta2-MG, CADP, MM, PCT
2019 Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes. AA, ADP, LTA, PFA, T2D, TXB2, WBA
2013 Effects of uncoupling protein 2 -866G/A polymorphism on platelet reactivity and prognosis in Chinese patients with type 2 diabetes and ischemic stroke. CADP, IS, TIA, UCP2
2013 In vitro effect of clinical propofol concentrations on platelet aggregation. CADP
2013 Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. AA, ADP, CADP, MA, PCI, PFA-100, PPI, RPR, STEMI
2013 Sample collection and platelet function testing: influence of vacuum or aspiration principle on PFA-100 test results. CADP
2013 Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction. CT, DD, HPR, vWF
2012 Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. CADP, CKD, CT, DES, PCI
2012 Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant. CADP
10  2011 Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia. PFA-100, vWF
11  2011 Prevalence of abnormal in vitro closure time using the Platelet Function Analyzer-100 in chronic kidney disease patients and analysis of associated factors. BUN, CADP, CHD, CKD, CPD, Cr, CT, eGFR
12  2010 Comparison of antiplatelet potency of sarpogrelate, aspirin, and beraprost in healthy volunteers according to in-vitro closure time. hs-CRP, vWF
13  2010 Do platelet function analyzer-100 testing results correlate with bleeding events after percutaneous renal biopsy? BP, CADP, PFA-100, PKB, PRBC, US
14  2010 Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. APTT, ASA, NSAIDs, PT
15  2010 The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis. ET, NPV, PFA, PPV, RT, Se, Sp
16  2009 A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. ---
17  2009 Genetics of platelet reactivity in normal, healthy individuals. CADP, COX-1, CT, ITGA2, PFA-100, vWF
18  2009 Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. CADP, CT, MDR1
19  2009 The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery. AA, ADPTPA, CABG, CADP, CT, IPA, TPA
20  2009 Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease. CADP
21  2008 Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. ADP, CT, RR
22  2008 Monitoring aspirin treatment in patients with thrombocytosis: comparison of the platelet function analyzer (PFA)-100 with optical aggregometry. CADP, CT, ET, PFA
23  2008 Variables that affect platelet function analyzer-100 (PFA-100) closure times and establishment of reference intervals in Korean adults. CADP, PFA-100
24  2008 Variation in platelet function testing has a major influence on detection of aspirin resistance in healthy subjects. CADP
25  2007 Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. ADP, CADP, CTs, vWFAg
26  2007 Hemodialysis shortens long in vitro closure times as measured by the PFA-100. CADP, ESRD, PFA-100
27  2007 Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. ACS, CADP, CT, PCI, PFA-100
28  2007 Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. AA, CADP
29  2007 [Reconfirmation of preanalytical variables and establishment of reference intervals of platelet function analyzer-100 closure times in Korean adults]. CADP, CT
30  2006 Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. CADP, CT, PCI
31  2006 Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. CAD, COX-1, GP
32  2005 Investigation of diagnostic importance of platelet closure times measured by Platelet Function Analyzer--PFA 100 in dogs with endotoxemia. CADP, Hct, WBC
33  2005 Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. BT, CADP, CT, PA, vWF
34  2004 High incidence of defective high-shear platelet function among platelet donors. CADP, CTs
35  2004 Platelet function abnormalities in qualified whole-blood donors: effects of medication and recent food intake. CADP
36  2003 Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. CADP, CTs, GP, PFA-100
37  2003 Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. PAD
38  2003 Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. CADP, SBT
39  2002 Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. CADP, CT, VWD
40  2002 The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. CADP, VWD
41  2000 Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. CADP, vWF
42  2000 Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. CADP, CT
43  2000 Platelet dysfunction detected at high shear in patients with heart valve disease. CABG, PFA, VR
44  1999 Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice? BT, CADP, PFA
45  1998 PFA-100 system: a new method for assessment of platelet dysfunction. ASA, CADP, CT